Cargando…
Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
BACKGROUND: Correct diagnosis of pleural effusion (PE) as either benign or malignant is crucial, although conventional cytological evaluation is of limited diagnostic accuracy, with relatively low sensitivity rates. METHODS: We identified biological markers accurately detected in a simple PE examina...
Autores principales: | Kremer, R, Best, L A, Savulescu, D, Gavish, M, Nagler, R M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853096/ https://www.ncbi.nlm.nih.gov/pubmed/20216542 http://dx.doi.org/10.1038/sj.bjc.6605607 |
Ejemplares similares
-
Salivary analysis of oral cancer biomarkers
por: Shpitzer, T, et al.
Publicado: (2009) -
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease
por: Reis, I M, et al.
Publicado: (2015) -
Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010) -
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006) -
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
por: Szpechcinski, A, et al.
Publicado: (2015)